system with universal population coverage, a policy of low contributions and narrow benefit packages with high co-payments has continued to ensure universal population coverage. Some necessary healthcare services are not covered by SHI, and Koreans often face high co-pay costs for healthcare services, including those that fall under SHI. Healthcare providers have an incentive to rapidly adopt new services and high-technology procedures that are not covered by the SHI because fees for such uncovered services are unregulated and are, therefore, substantially higher. Consequently, as of 2004, roughly 40% of healthcare payments in Korea were not covered by SHI and were paid directly by patients (Kim and Jung 2005) . These high payments impose substantial economic burden on Korean households, especially in cases in which individuals suffer from catastrophic diseases such as cancer. Hence, Koreans rely upon supplementary private health insurance (SPHI) to cover their healthcare costs. The sale of SPHI plans for catastrophic diseases, particularly cancers, has been growing since the 1980s. As of 2005, the total premiums paid for SPHI had increased to approximately half of those for SHI (Jung et al. 2006) . SPHI status is assumed to affect clinical treatment and outcome of stomach cancer patients because, as noted above, the coverage of SHI is not full and the role of SPHI becomes crucial to their healthcare payments in Korea. Herein, we have examined the relationships between SPHI and the stage of cancer at diagnosis, treatment, the utilization of medical services, and survival among stomach cancer patients in Korea. To our knowledge, no prior study has investigated these relationships, although some previous studies have focused on patients with the major cancers such as colorectal, breast, and prostate cancer. In addition, the current study comprehensively examined diagnosis, treatment, utilization, and outcomes, while other studies have only focused on a single aspect of cancer care (Roetzheim et al. 1999; Roetzheim et al. 2000; Kelz et al. 2004; Hall et al. 2005) .
PATIENTS AND METHODS

Inclusion and exclusion criteria
The authors performed a retrospective cohort study of 4,137 patients who, between 2000 and 2003, were diagnosed with stomach cancer (with no previous history of cancer at any site) and underwent a radical gastrectomy in a tertiary care hospital in Korea. This study excluded patients who were younger than 30 years old (n = 60) and those who were not insured by Korean SHI (n = 46). Patients who underwent gastric bypass surgery or exploratory laparotomy (n = 251) because stomach cancer had spread to other organs were also excluded. The final sample included 3,780 patients who underwent a total or subtotal gastrectomy. Patients who were excluded based on the above criteria did not differ significantly in gender or stage of cancer at diagnosis from those who were included in the study.
Clinical data collection
Data for patients who underwent a radical gastrectomy was obtained from the stomach cancer surgery database at Samsung Medical Center (SMC). SMC is one of the leading hospitals in Korea for radical gastrectomy, and the proportion of patients treated for cancer at SMC was 6% of the total number of patients with cancer in the country in 2002 (MOHW 2003) . The SMC stomach cancer surgery database provided all of the clinical data for this study, including age, gender, stage of cancer at diagnosis, number of comorbidities at operation, year of procedure, surgery type, surgery doctor, and mode of therapy (i.e., adjuvant chemotherapy or radiotherapy).
Socioeconomic, utilization, and survival data collection
Information on the patients' socioeconomic factors (residence, occupation, SPHI status, SHI type) and medical service utilization (physician visits, length of stay) was available from SMC claims for both inpatients and outpatients. We used the death certificate database available from the Korea National Statistical Office for survival analysis. This study used unique 13-digit personal identification numbers to merge the SMC stomach cancer surgery database and the death certificate database. The Institutional Review Board of the SMC approved the protocol.
Description of variables
We defined the group of "SPHI insured" as those who had a medical certificate issued by SMC entitling them to receive SPHI benefits for cancer treatment. Cancers were staged according to the tumor metastasis (TNM) classification system, which was established by the Union International Contra la Cancrum (UICC). This study defined survival time as the number of days between the radical gastrectomy and death (or until December 31, 2006 for survivors). Table  1 provides a description of the variables used in this study. 
Statistical analysis
This study used simple frequencies to describe characteristics of the study population. We used a t-test or a chi-square test to detect significant differences between the SPHI group and the non-SPHI group in terms of demographic characteristics, socioeconomic status, clinical characteristics, and medical service utilization. We used a log-rank test to detect significant differences between the two groups in survival time after receiving the radical gastrectomy.
A multiple logistic regression model was developed to examine the relationship between mode of therapy and SPHI with adjustment for demographic characteristics, socioeconomic status, stage of cancer at diagnosis, number of comorbidities at operation, surgery type, and surgery doctor. The model was indicated by odds ratios (ORs) and 95% confidence intervals (CIs). The authors also conducted an ordinary least squares (OLS) regression model to identify the relationship between physician visits and SPHI with adjustment for mode of therapy and length of stay plus the covariates used in the multiple logistic regression model. Finally, the survival model in this study used Cox's proportional hazards regression analysis to describe the association between survival time and SPHI with adjustment for physician visits plus the covariates used in the OLS regression model. The survival model was indicated by risk ratios (RRs) and 95% CIs. With the exception of the univariate model, we set the significance level at p < 0.1. All analyses were performed using the SAS statistical package (version 9.1; SAS Institute, Cary, NC, USA). Table 2 summarizes patient demographics, socioeconomic status, clinical characteristics, and medical service utilization according to SPHI status. Approximately 36% of all patients had one or more SPHI plan at the time of their stomach cancer diagnosis. The mean age of all patients was 58 years, but SPHI patients were significantly younger than non-SPHI patients (53 years versus 61 years, respectively; p < 0.001). Males represented 66% of all patients, and no significant difference was observed in SPHI status according to gender ( p = 0.15). The proportion of white-collar workers among all workers was higher in the insured than in the uninsured group (24% versus 18%, p < 0.001). Over half (52%) of the subjects in this study lived in the Seoul metropolitan area.
RESULTS
Univariate analysis of SPHI and non-SPHI patients' characteristics
As shown in Table 2 , 64% of all subjects were diagnosed at the first stage of cancer, and no significant difference in cancer stage was observed between the SPHI and the non-SPHI patients ( p = 0.91). The average number of comorbidities at the time of operation was 1.1; comorbidities were significantly less prevalent among the SPHI patients (0.9) compared to the non-SPHI patients (1.1, p < 0.001). In terms of surgical treatment, 74% of all subjects required a subtotal gastrectomy, and 92% of all subjects received the surgery from a senior surgeon who typically performed more than 100 such procedures per year. In addition, 28% of all patients underwent adjuvant chemotherapy or radiotherapy, and these therapies were more frequent among SPHI patients (34%) than non-SPHI patients (25%, p < 0.001).
Three years after a radical gastrectomy, the average number of physician visits for all patients was 24, and we observed a significant difference between the SPHI (27 visits) and the non-SPHI patients (22 visits, p < 0.001). However, no significant differences were observed in the length of stay over the same period (19 days versus 19 days, respectively; p = 0.56). Among all patients, 829 deaths (22%) occurred during the follow-up period. A significant difference in all-cause mortality was observed between the two groups, with the SPHI group showing greater survival compared to the non-SPHI group ( p < 0.001) (Fig. 1) .
Multiple logistic regression analysis of SPHI and adjuvant therapy
Data in Table 3 (first column) demonstrate that there was no significant difference in the number of the insured and the uninsured patients who received adjuvant chemotherapy or radiotherapy (OR = 1.14, p = 0.21). Adjuvant chemotherapy or radiotherapy was significantly less frequent with advanced age (OR for patients ≥ 70 years = 0.08, p < 0.001), but it was significantly more frequent during 2003 (OR = 2.53, p < 0.001) and when the patient had an advanced stage of cancer at the time of diagnosis (OR for patients at stage IV = 132.92, p < 0.001). In addition, we observed a significant difference in the treatment received by radical gastrectomy patients based on the surgeon (OR for surgeon D = 0.60, p = 0.009). However, the patients who underwent adjuvant chemotherapy or radiotherapy did not differ in gender, occupation, SHI type, number of comorbidities at the time of operation, or surgery type.
Multiple OLS regression analysis of SPHI and physician visits
The SPHI group was 5% more likely to visit a physi- cian than the non-SPHI group ( p < 0.001) (Table 3 (second  column) ). The number of physician visits differed significantly according to residence, occupation, year of procedure, and surgery doctor. The number of visits to a physician also increased according to the stage at diagnosis, peaking in patients with stage II cancer ( p < 0.001) and then decreasing from stage IIIa onward ( p = 0.028). We found a positive correlation between the number of physician visits and the use of adjuvant treatment and the length of stay ( p < 0.001 for both).
Cox's proportion hazard regression analysis
The third column in Table 3 shows the adjusted RRs of the SPHI patients for all causes of mortality. Our results indicate that the SPHI group was more likely to survive stomach cancer than the non-SPHI group (RR = 0.84, p = 0.03). All-cause mortality for radical gastrectomy patients increased with age (RR for patients ≥ 70 years = 1.68, p = 0.001), stage at diagnosis (RR for stage IV = 30.20, p < 0.001), use of adjuvant chemotherapy or radiotherapy (RR = 1.43, p = 0.001), and the length of stay (RR = 2.72, p < 0.001). However, mortality decreased with the number of physician visits (RR = 0.61, p < 0.001).
DISCUSSION
The current study examined the relationship between SPHI and four processes and outcomes; diagnosis, treatment, utilization of health services, and survival among stomach cancer patients. This is a novel approach, as previous research has only accounted for a limited number of processes among cancer patients (Roetzheim et al. 1999; Roetzheim et al. 2000; Kelz et al. 2004; Hall et al. 2005) . In short, the authors showed that SPHI was a determinant of physician visits and survival among stomach cancer patients, but not a predictor of stage of cancer at diagnosis and adjuvant therapy.
Previous studies in the United States have suggested that health insurance status and the type of insurance purchased are important factors in diagnosing cancer at an early stage (Ayanian et al. 1993; Riley et al. 1994; Roetzheim et al. 1999; Lee-Feldstein et al. 2000; Chen et al. 2007; Halpern et al. 2007 ). These results are likely observed because being uninsured or inadequately insured prevents early detection. Even studies among Europeans who have general access to public health care indicated that SPHI increased the utilization of cancer screening services and thus, cancer diagnosis at an early stage (Borras et al. 1999; Gallina et al. 2007 ). Hence, our finding that SPHI did not have an effect on the stage of cancer at diagnosis among Korean cancer patients was unexpected. These results may be explained by the fact that the majority of SPHI plans in Korea cover very few cancer screens or prevention services. Instead, they pay a fixed amount to their enrollees after cancer diagnosis, and the patients are then responsible for purchasing their own health care services. These results suggest that the effects of SPHI on the stage of cancer at diagnosis depend on methods of reimbursement for enrollees. On the other hand, as of 2001, the rate of prevalence of stomach cancer was 1.29 per 1,000 persons in Korea, higher than that of lung cancer (0.35 per 1,000 persons) or that of liver cancer (0.26 per 1,000 persons) (MOHW 2002) . Therefore, Korean people have been attentive toward detecting stomach cancer. The participation rate of the organized screening program covered by SHI was 42% of its enrollees, as of 2001 (NHIC 2003) , and there were many opportunistic screening programs provided by hospitals in Korea. These facts have resulted in an early detection of stomach cancer. Our findings showed that 64% of all subjects were diagnosed at the first stage.
Although a univariate analysis indicated that the number of patients who underwent adjuvant chemotherapy or radiotherapy after a radical gastrectomy differed with SPHI coverage (p < 0.001), this distinction disappeared in the multiple model that was adjusted for covariates (OR = 1.14, p = 0.21). These results are not consistent with previous studies that showed a significant difference in treatment patterns among breast cancer patients according to health insurance status (Bradley et al. 2002; Richardson et al. 2006) . Because all Koreans have access to SHI or Medical Aid, which cover most adjuvant therapies for stomach cancer and require low co-payment (20% of total discharge) for them, these services are easily accessible for both SPHI and non-SPHI individuals. On the other hand, these results may be due to the unique characteristics of Korean SPHI, which directly pays a fixed amount of money to each subscriber who is responsible for purchasing his or her own healthcare services. As the needed adjuvant therapies are covered by SHI, SPHI patients might not need to purchase additional adjuvant therapies.
However, we found that SPHI coverage was an important predictor of the number of visits that patients made to their physician after a radical gastrectomy. These results indicated that SPHI facilitated greater access to physician care, as high co-payment (50% of total discharge) for physician visits is an obstacle for non-SPHI individuals. The results of this study are in agreement with previous investigations that examined the relationship between physician visits and SPHI coverage in Korea (Kang et al. 2005; Jung et al. 2006) . The current findings are also consistent with studies that examined the effects of SPHI on health care utilization in the United States (Ettner 1997) , France (Buchmueller et al. 2004) , Ireland (Harmon et al. 2001), and Spain (Vera-Hernandez 1999) . We would also like to note that in the current study, the multiple OLS regression model of SPHI and physician visits was adjusted for the use of adjuvant chemotherapy or radiotherapy, the length of hospital stay, and the number of comorbidities, which were not considered in previous analyses.
In the univariate analysis, we found that SPHI patients survived longer than non-SPHI patients ( p < 0.001). This result has two likely explanations. First, SPHI may improve survivorship by allowing for an earlier diagnosis (Lee-Feldstein et al. 2000; Gallina et al. 2007) . Second, SPHI coverage may result in better access to cancer treatments and increase medical service utilization, which increase the survival rate among cancer patients (Roetzheim et al. 2000; Bradley et al. 2002; Hall et al. 2005) . Hence, it is necessary to perform multiple analysis that is able to control for early diagnosis, type of cancer treatment, and utilization (number of physician visits and length of stay) in order to directly examine the effect of SPHI on the survival of gastrectomy patients.
Although the Cox's proportional hazard regression model used in this study was adjusted for the stage of cancer at diagnosis, the use of adjuvant therapy, and utilization (as defined above), the model still detected a significant difference in survivorship between the two groups (RR = 0.84, p = 0.03). Based on the results of the univariate and a multiple analysis of SPHI and survival, attention should be given to socioeconomic characteristics such as income and education. While these characteristics are omitted in the multiple analyses they are known to play important roles in cancer survivorship and in whether or not a person purchases SPHI. Many recent studies have shown that SPHI is much more prevalent among wealthier, well-educated individuals in Western countries (Ettner 1997; Harmon and Nolan 2001; Buchmueller et al. 2004 ) and in Korea (Yoon et al. 2005) . In general, people with higher incomes or education also survive longer than their counterparts (Boyd et al. 1999; Steenland et al. 2004) . Therefore, because income and education are positively associated with both the purchase of SPHI and survival rates, the observed difference in survival rates between the SPHI and the non-SPHI patients may be attributable to the confounding effects of income and education; however, we were unable to examine these effects in the current study.
This study has several limitations. First, because this was a non-experimental, retrospective cohort study, the authors could not determine causality between SPHI status and the number of physician visits/survival rate. Our results may have been confounded by several unobservable characteristics, such as preferences for medical services and the socioeconomic status of the patient. Second, SPHI status was assessed only at the time of visiting SMC and may have changed during the follow-up period. Finally, these results may not be representative of the general population because the patients were all obtained from one medical center in Korea.
The effects of SPHI on healthcare process and outcomes depend on the scope of SHI coverage. Therefore, further research is necessary to examine the relationships between SPHI and the healthcare process and patient outcomes for catastrophic diseases (e.g., lung cancer) that may require higher payments than does stomach cancer. Performing a time series study that compares effects of SPHI on the healthcare process and outcomes according to time may be meaningful because the Korean government is enlarging the scope of SHI benefit coverage and is lowering the SHI co-payment for physician visits. In addition, because the method of reimbursement in SPHI is changing from a fixed benefit system to an incurred expense-based benefit system, further research should compare the effects of SPHI on the healthcare process and outcomes according to methods of SPHI reimbursement.
In conclusion, the authors showed that SPHI was a determinant of healthcare utilization and survival among stomach cancer patients. This study suggests that the effects of SPHI on the four subsequent healthcare process and outcomes (diagnosis, treatment, utilization, survival) depend on the scope of SHI coverage, as well as on the method of reimbursement of SPHI. Hence, it is necessary to consider the relationship between SHI and SPHI when health policymakers account for the role of SPHI in financing medical services within a national health care system. The results of our study serve as a reference for, in particular, policymakers in other countries where there is private health insurance which is suplementary to SHI.
